PE20231943A1 - Formulacion combinada oral que incluye gemigliptina y dapagliflozina y metodo de preparacion para la misma - Google Patents
Formulacion combinada oral que incluye gemigliptina y dapagliflozina y metodo de preparacion para la mismaInfo
- Publication number
- PE20231943A1 PE20231943A1 PE2023001386A PE2023001386A PE20231943A1 PE 20231943 A1 PE20231943 A1 PE 20231943A1 PE 2023001386 A PE2023001386 A PE 2023001386A PE 2023001386 A PE2023001386 A PE 2023001386A PE 20231943 A1 PE20231943 A1 PE 20231943A1
- Authority
- PE
- Peru
- Prior art keywords
- preparation
- weight
- gemigliptin
- dapagliflozin
- pharmaceutically acceptable
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 5
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 title abstract 3
- ZWPRRQZNBDYKLH-VIFPVBQESA-N Gemigliptin Chemical compound C([C@@H](N)CC(=O)N1CC2=C(C(=NC(=N2)C(F)(F)F)C(F)(F)F)CC1)N1CC(F)(F)CCC1=O ZWPRRQZNBDYKLH-VIFPVBQESA-N 0.000 title abstract 3
- 229960003834 dapagliflozin Drugs 0.000 title abstract 3
- 229960002458 gemigliptin Drugs 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- 239000003085 diluting agent Substances 0.000 abstract 2
- 239000007884 disintegrant Substances 0.000 abstract 2
- 239000000314 lubricant Substances 0.000 abstract 2
- 229920002785 Croscarmellose sodium Polymers 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 abstract 1
- 229960001681 croscarmellose sodium Drugs 0.000 abstract 1
- 229960000913 crospovidone Drugs 0.000 abstract 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 abstract 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 abstract 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 abstract 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 abstract 1
- 239000011885 synergistic combination Substances 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20200131868 | 2020-10-13 | ||
PCT/KR2021/014013 WO2022080815A1 (ko) | 2020-10-13 | 2021-10-12 | 제미글립틴 및 다파글리플로진을 포함하는 경구용 복합제제, 및 이의 제조 방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20231943A1 true PE20231943A1 (es) | 2023-12-05 |
Family
ID=81208465
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2023001386A PE20231943A1 (es) | 2020-10-13 | 2021-10-12 | Formulacion combinada oral que incluye gemigliptina y dapagliflozina y metodo de preparacion para la misma |
Country Status (10)
Country | Link |
---|---|
KR (1) | KR20220048952A (zh) |
CL (1) | CL2023001014A1 (zh) |
CO (1) | CO2023006028A2 (zh) |
CR (1) | CR20230161A (zh) |
DO (1) | DOP2023000071A (zh) |
EC (1) | ECSP23027106A (zh) |
MX (1) | MX2023004218A (zh) |
PE (1) | PE20231943A1 (zh) |
TW (1) | TWI826841B (zh) |
WO (1) | WO2022080815A1 (zh) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180058510A (ko) * | 2016-11-24 | 2018-06-01 | 한미약품 주식회사 | 다파글리플로진 l-프롤린을 포함하는 약제학적 제제 |
WO2018124497A1 (ko) * | 2016-12-30 | 2018-07-05 | 한미약품 주식회사 | 다파글리플로진 l-프롤린과 항당뇨병제를 포함하는 약제학적 복합 제제 |
KR20180078762A (ko) * | 2016-12-30 | 2018-07-10 | 한미약품 주식회사 | 다파글리플로진 l-프롤린을 포함하는 당뇨병 질환의 예방 또는 치료용 약제학적 조성물 |
KR102204439B1 (ko) | 2018-05-14 | 2021-01-18 | 에이치케이이노엔 주식회사 | Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물 |
-
2021
- 2021-10-12 WO PCT/KR2021/014013 patent/WO2022080815A1/ko active Application Filing
- 2021-10-12 KR KR1020210134776A patent/KR20220048952A/ko not_active Application Discontinuation
- 2021-10-12 PE PE2023001386A patent/PE20231943A1/es unknown
- 2021-10-12 CR CR20230161A patent/CR20230161A/es unknown
- 2021-10-12 MX MX2023004218A patent/MX2023004218A/es unknown
- 2021-10-13 TW TW110138009A patent/TWI826841B/zh active
-
2023
- 2023-04-06 CL CL2023001014A patent/CL2023001014A1/es unknown
- 2023-04-12 DO DO2023000071A patent/DOP2023000071A/es unknown
- 2023-04-13 EC ECSENADI202327106A patent/ECSP23027106A/es unknown
- 2023-05-11 CO CONC2023/0006028A patent/CO2023006028A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CL2023001014A1 (es) | 2023-12-11 |
KR20220048952A (ko) | 2022-04-20 |
MX2023004218A (es) | 2023-04-21 |
ECSP23027106A (es) | 2023-05-31 |
DOP2023000071A (es) | 2023-07-09 |
TWI826841B (zh) | 2023-12-21 |
CR20230161A (es) | 2023-09-21 |
CO2023006028A2 (es) | 2023-07-10 |
TW202228701A (zh) | 2022-08-01 |
WO2022080815A1 (ko) | 2022-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY38425A (es) | Procesos novedosos para preparar n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1- isopropil-1h-pirazol-3-sulfonamida y sales de éste | |
GT200600096A (es) | Composicion farmaceutica para el tratamiento del cancer | |
AR057946A1 (es) | Formulacion de zonisamida de liberacion sostenidda | |
MX2021015056A (es) | Compuesto de pirrolopirimidina y uso del mismo. | |
CO2022004723A2 (es) | Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1 | |
PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
DOP2021000103A (es) | Pirazoles como moduladores de hemoglobina | |
CL2021002107A1 (es) | Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria. | |
CL2022001317A1 (es) | Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma. | |
CO2023013050A2 (es) | Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas | |
CO2022006087A2 (es) | Métodos para el tratamiento de la trombocitopenia inmunitaria mediante la administración de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidino-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrilo | |
ECSP19084722A (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
PE20231943A1 (es) | Formulacion combinada oral que incluye gemigliptina y dapagliflozina y metodo de preparacion para la misma | |
AR054442A1 (es) | Formas de dosificacion, composiciones farmaceuticas y metodos para el suministro sub-tenon | |
PA8549401A1 (es) | Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido | |
CO2023000523A2 (es) | Composiciones farmacéuticas que comprenden venglustat | |
CL2022000320A1 (es) | Compuestos adecuados para el tratamiento y la profilaxis del desgaste muscular y otras afecciones | |
BR112018008835A2 (pt) | composição farmacêutica oral, composição farmacêutica de liberação pulsátil oral, método para tratar uma condição de doença que requer terapia com fumarato de dimetila e método para tratar esclerose múltipla | |
CO2021014967A2 (es) | Composiciones farmacéuticas de combinación a dosis fijas de liberación inmediata, métodos y usos de las mismas | |
AR127170A1 (es) | Antagonistas del receptor de la hormona paratiroidea (pth) y sus usos | |
AR122297A1 (es) | Composiciones sólidas que comprenden un agonista del glp-1, un inhibidor del sglt2 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico | |
AR128113A1 (es) | Composiciones que contienen fexofenadina | |
MX2022004809A (es) | Composiciones para prevenir o tratar enfermedad pulmonar obstructiva cronica (epoc). | |
CO2020002287A2 (es) | Composiciones farmacéuticas | |
CO2022011987A2 (es) | Usos y composiciones a base de polifenoles para mejorar la biodisponibilidad oral del hidroxitirol |